National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.

Rapid Review

Commenced Completed Outcome
19/10/2011 02/11/2011 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
01/02/2012 19/06/2012  Reimbursement recommended.

The NCPE believe that apixaban is cost effective for the prevention of VTE following total hip replacement and total knee replacement.

 Apixaban (Eliquis) Summary